ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1681

Assessment of Patients With Takayasu’s Arteritis in Routine Clinical Follow-Up With Indian Takayasu Clinical Activity Score 2010(ITAS2010)

Fatma Alibaz-Oner and Haner Direskeneli, Rheumatology, Marmara University, School of Medicine, Istanbul, Turkey

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Takayasu arteritis

  • Tweet
  • Email
  • Print
Session Information

Title: Vasculitis II

Session Type: Abstract Submissions (ACR)

Background/Purpose: ITAS2010 (Indian Takayasu Clinical Activity Score) is a new composite index developed to assess clinical activity in Takayasu’s arteritis (TAK), which is weighted for vascular items. In this study, we aimed to investigate the effectiveness of ITAS2010 in the routine clinical follow-up of patients with TAK. 

Methods: Patients (n=33, mean age:40.9±12,4 years, F/M:30/3) classified according to ACR  criteria for TAK were enrolled. ITAS2010 forms were filled cross-sectionally at baseline for all clinical features and 2 follow-up visits prospectively, with intervals of at least 4-6 months, by including only new or worsening symptoms within the past 3 months(1). 

Results: ITAS2010 was similar at baseline for both active and inactive patients [12 (5-20) vs 10 (0-19), respectively]. There was no correlation between ITAS2010 and acute phase reactants (APRs) in this visit. Similarly, change according to PGA was not reflected in ITAS in the second visit [1,15 (0-6) vs 1,4 (0-3), respectively]. Only in the third visit ITAS2010 score was observed to be significantly higher in active [1,62 (0-7)] patients compared to inactives [0,45 (0-3)](p=0,001). The total agreement between ITAS2010 and PGA was 60% (kappa: 0,096, p=0,43) and between ITAS2010 and Kerr et al. was 74% (kappa: 0,18, p=0,035). The total agreement between PGA and Kerr et al. was 71% (kappa: 0,26, p=0,005). Twelve patients were evaluated with imaging in the follow-up period (4 with PET, 8 with MR-Angiography). When we added an extra score on ITAS2010 for high APRs or positive imaging (vascular progression with radiology or increased uptake on major vascular structures with PET), the total agreement between ITAS2010 and PGA increased to 74% (kappa: 0,499, p<0,001), whereas ITAS2010 and Kerr et al. decreased to 51% (kappa: 0,102, p=0,06). 

Conclusion: The agreement between PGA and ITAS2010 was observed to be limited in our study. However, when we combined ITAS2010 with APR or imaging, our results improved. ITAS2010 had a significant discriminatory value according to disease activity in only the third visit in our routine follow-up. These results suggest that ITAS2010 may be valuable in the long-term follow-up of patients with TAK, especially if combined with biomarkers and imaging.

Reference:

1)  Misra R, Danda D, Rajappa SM, Ghosh A, Gupta R, Mahendranath KM, Jeyaseelan L, Lawrence A, Bacon PA; on behalf of the Indian Rheumatology Vasculitis (IRAVAS) group. Development and initial validation of the Indian Takayasu Clinical Activity Score (ITAS2010). Rheumatology (Oxford). 2013 Apr 16. [Epub ahead of print]


Disclosure:

F. Alibaz-Oner,
None;

H. Direskeneli,
None.

  • Tweet
  • Email
  • Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/assessment-of-patients-with-takayasus-arteritis-in-routine-clinical-follow-up-with-indian-takayasu-clinical-activity-score-2010itas2010/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology